Atrion (Atrion) ROCE % : 11.71% (As of Dec. 2023)

View and export this data going back to 1972. Start your Free Trial

What is Atrion ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Atrion's annualized ROCE % for the quarter that ended in Dec. 2023 was 11.71%.

Atrion ROCE % Historical Data

The historical data trend for Atrion's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atrion ROCE % Chart

Atrion Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

17.18

14.15

15.15

16.23

9.10

Atrion Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															14.04	7.28	12.34	5.77	11.71

Atrion ROCE % Calculation

Atrion's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	22.524	/	( ( (264.712 - 18.098)	+	(260.825 - 12.621) )	/ 2 )
	=	22.524	/	( (246.614	+	248.204)	/ 2 )
	=	22.524	/	247.409
	=	9.10 %

Atrion's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	29.152	/	( ( (264.809 - 15.266)	+	(260.825 - 12.621) )	/ 2 )
	=	29.152	/	( ( 249.543	+	248.204 )	/ 2 )
	=	29.152	/	248.8735
	=	11.71 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Atrion (NAS:ATRI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Atrion ROCE % Related Terms

Thank you for viewing the detailed overview of Atrion's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Atrion (Atrion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atrion Corp (NAS:ATRI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Allentown Parkway, Allen, TX, USA, 75002-4211

Website

https://www.atrioncorp.com

Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.

Executives

Preston G Athey	director	ONE ALLENTOWN PKWY, ALLEN TX 75002
David A Battat	officer: President & CEO	2700 HALKEY-ROBERTS PLACE NORTH, ST. PETERSBURG FL 33716-4103
Jeannette Bankes	director	ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Morgan Hugh J Jr	director
Ronald Nicholas Spaulding	director	ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Cindy Ferguson	officer: Officer/ CFO	ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffery Strickland	officer: Vice President & CFO
Emile A Battat	director, officer: Chairman	ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Maria Sainz	director	C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Stupp John P Jr	director	STUPP JOHN P JR, #18 ST. ANDREWS DR., ST LOUIS MO 63124
Roger F Stebbing	director
Ronald N Spaulding	director	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Richard O Jacobson	director	ONE ALLENTOWN PARKWAY, C/O ATRION, ALLEN TX 75002
Maley John H P	director	6 ROCK CREST LANE, SIGNAL MOUNTAIN TN 37377
Margaret Maxwell Zagel	director	C/O TELLABS OPERATIONS INC, 4951 INDIANA AVE, LISLE IL 60532